查詢結果分析
相關文獻
- Morbidity with Contemporary Transrectal Biopsy of the Prostate
- 臺灣地區之前列腺癌
- The Role of Percent Free-Prostate Specific Antigen (PSA) in Patients with Total PSA Levels between 4.0 and 10.0 ng/ml
- Prostatic Carcinoma with Brain Metastasis Presenting as a Tumor Hemorrhage
- 前列腺癌腫瘤標記(PSA)最新應用及發展
- 罹患前列腺癌的危險因子--類胰島素生長因子I(IGF-I)
- Rectal Stenosis: An Unusual Presentation of Prostate Adenocarcinoma
- 前列腺癌
- 協助一位住院的前列腺癌患者及家屬渡過癌末的護理經驗
- Application of Cryoablation in the Management of Prostate Cancer
頁籤選單縮合
題 名 | Elevated Serum Chromogranin a Precedes Prostate-Specific Antigen Elevation and Predicts Failure of Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer=進展性前列腺癌病患血中Chromogranin-A濃度之上升先於PSA值變化可早預期 |
---|---|
作 者 | 莊正鏗; 吳竹蘭; 曹國倩; 廖順奎; | 書刊名 | 臺灣醫學會雜誌 |
卷 期 | 102:7 2003.07[民92.07] |
頁 次 | 頁480-485 |
分類號 | 415.1461 |
關鍵詞 | 前列腺癌; Androgen antagonists; Chromogranins; Drug resistance; Neurosecretory systems; Prostatic neoplasms; |
語 文 | 英文(English) |
英文摘要 | Background and Purpose: Development of hormone-refractory prostate cancer (HRPC) may be due to outgrowth of neuroendocrine cells in the prostate gland. Increase in prostate-specific antigen (PSA) levels usually precedes clinical progression in patients failing hormone therapy. The timing of changes of PSA and chromogranin A (CgA) remains unclear. We analyzed serial serum levels of CgA and PSA in prostate cancer patients receiving androgen deprivation therapy (ADT). Methods: From October 1998 through January 2003, 90 patients with locally advanced (n=20) or metastatic (n=70) prostate cancer receiving ADT were enrolled. Serial serum samples for PSA and CgA assay were collected before and every 3 months during ADT. The median follow-up was 35 months (range, 20 to 52 months). Results: At least 3 serum samples were obtained during ADT in 78 patients. Among these patients, 36 (46.2%) had no PSA re-elevation (<4ng/mL) and their CgA remained low (<84.6 ng/mL) throughout the treatment period. Another 17 patients (21.8%) also had low PSA (<4.0 ng/mL) but had progressively increasing CgA. The remaining 25 patients (32%) developed HRPC. Among them, 17 showed progressive elevation in CgA (>100 ng/mL), which was followed by PSA elevation after a median interval of 10 months. Interestingly, CgA levels decreased again upon reaching plateaus as PSA began to rise. Conclusions: For patients with advanced prostate cancer receiving ADT, serum CgA may be a useful tumor marker that precedes PSA elevation. Elevation of CgA during ADT signals ultimate treatment failure and may have clinical implications for implementation of novel therapies. |
本系統中英文摘要資訊取自各篇刊載內容。